View more on these topics

Octopus picks up on bioscience

When asked about the investment philosophy of the company

Dilke-Wing says: “This is a complex area beyond the remit of most

advisers, including me. You either buy into the biotech philosophy

and accept the fact that you leave the stock selection to the

specialists, or you view it as a sector that is too speculative to be of

interest to all but a minority of clients.”



Burke calls the philosophy fine, but says that investments in this

sector which concentrate on new businesses should not be expected

to yield early results.

Upton says: "There is certainly a strong investment case on this

theme, so given the input of all those involved, the philosophy seems

sound."

Casting an eye over the drawbacks of the trust Burke says:

"Investments of this nature may take some time to bear

fruit." Upton is in agreement.

Dilke-Wing says: "The disadvantage of the trust is that it is

being promoted into a market where existing venture capital trusts

are already undersubscribed by approximately £200 m, by a relatively

unknown promoter into an undeniably niche investment

sector."

Looking at Octopus&#39 reputation Upton says: "Unfortunately, I do

not know enough about Octopus." Dilke-Wing has also never

heard of them before.

Burke says: "I have no first hand experience of Octopus Asset

Management, but the background of the directors looks impressive,

with the founders formerly being managers and analysts with Mercury

Asset Management."

Considering the trust which may provide the main competition

Dilke-Wing says: "There are a lot of trusts out there at the

moment, with, one assumes, a fair number waiting in the wings.

Notable competitors include Aberdeen, Electra, Pennine, Downing,

Isis, Baronsmeand and Quester."

Burke feels that in the current climate, more diversified general

venture capital trust funds are likely to attract a higher proportion of

the available investors funds.

Moving on to whether the charges are fair and reasonable Upton

says: "Compared to other products, the charges seem high,

with the investment manager and technology adviser both taking an

annual management fee. A performance fee for a 7 per cent average

seems incredibly low considering the optimistic claims made of their

past performance in the prospectus."

Burke says that at first glance some aspects of the charges seem

high, but he feels the technology advice fee will potentially also help

with the introduction of quality investment opportunities, and therefore

the total charges are realistic.

Dilke-Wing says: "Overall running costs on an annual basis are

high, particularly if there is not full take up. Performance fees appear

to be standard."

Commenting on the commission Burke says: "2.25 per cent

initial commission and a 0.25 per cent trail commission for the next

four years is reasonable but nothing great. Trail commission does

increase to 0.3 per cent or 0.4 per cent depending on the aggregate

total of business introduced by the adviser."

Dilke-Wing feels the commission is pretty standard for this type of

product. Upton says: "I think the commission is slightly on the

lean side plus trail commission finishes after four years – I cannot

quite see the logic there."

Considering the product literature provided Dilke-Wing says: "I

thought the product literature was very good. I would need a strong

story to be convinced to put money in this issue and, given the

obvious limitations, I thought the brochure put a coherent case in a

concise fashion."

Upton calls the literature excellent and says he enjoyed reading it.

Burke says: "Given the constraints imposed on a prospectus of

this nature, the literature is quite readable."

Recommended

Any payment method suits me

As an adviser who charges fees and takes commission (invar-iably partially rebated), I really do not care how I am paid as long as it is sufficient (in my view) for the work undertaken. I get irritated by providers manipulating their charging and remuneration structures to suit those who are coy about how much they […]

Genesis Home Loans 2-year discount

Genesis Home Loans, discounted mortgageDiscounted term: 2 yearsDiscount: 1.25%Payable rate: 4.75%Minimum loan: £40,000Maximum loan: £250,000Income multiples: 3.25 +1, 2.75 x jointArrangement fee: £325Redemption fee: 6 months interest at SVR during discount periodConditions: max 80% LTV for first time buyersIntroducer&#39s fee: refer to packagerTel: 01832 275 044

Make income protection work

The board of my firm has decided to increase the benefits package we offer to senior employees and feel some form of sickness insurance would be most useful, both to the company and to the employees themselves. How do you suggest we should proceed? We are a firm of accountants and the scheme would initially […]

Equity-release code is more important than ever, says King

The delay in bringing mortgages under the regulatory wing of the FSA has highlighted the importance of the code used to maintain standards in the equity-release market, according to its trade body.The newly appointed chairman of Safe Home Income Plans, Jon King, says the Ship code is more important than ever after the delay to […]

Navigating volatility

The making of any fund can be seen in how it responds to crises and opportunities. In this short video, Head of Multi Asset at Royal London Asset Management Trevor Greetham outlines how the Royal London Global Multi Asset Portfolios or GMAPs navigated through Brexit and the US election cycle. He also highlights the importance […]

Newsletter

News and expert analysis straight to your inbox

Sign up

Comments

    Leave a comment